Have thought for a while that they are seriously undervalued. Nice suite of products, sales building, inroads into china, enlarging there chain of distributors, lowering expenses, think there are good synergies with the THOR aquisition and they have expanded manufacturing resources. Same FDA rebate as atcor but significantly cheaper product.
Chair has a lot of skin in the game.
Surely once they role out the rebranded THOR products and the BP+ product they are going to brake over into profitability and re-rating.
Negatives, seriously illiquid and has been no clearing of any overhang from the recent cr.
Email from Rob, page-21
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add UCM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.506M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 150000 | 1.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.2¢ | 200000 | 1 |
View Market Depth
| Last trade - 16.12pm 29/11/2024 (20 minute delay) ? |
| UCM (ASX) Chart |
Day chart unavailable
